The UK-based AI technology company Healx has begun a partnership with the Foundation for Angelman Syndrome Therapeutics (FAST), focusing on developing new therapies for the rare neurogenetic disorder.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback